Zobrazeno 1 - 10
of 98
pro vyhledávání: '"Maja Noman"'
Autor:
An Outtier, Liese Gijbels, Maja Noman, Bram Verstockt, João Sabino, Séverine Vermeire, Marc Ferrante
Publikováno v:
Inflammatory bowel diseases.
Background Patients with inflammatory bowel diseases (IBD) sometimes require investigational medicinal therapy in a clinical trial. Before enrollment, patients must meet strict eligibility criteria, hampering recruitment rates. We investigated the ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f412d57c0a82df631351028c5d1c3c31
https://pubmed.ncbi.nlm.nih.gov/36350998
https://pubmed.ncbi.nlm.nih.gov/36350998
Autor:
Karen Rans, Gert De Hertogh, Gert Van Assche, Marc Ferrante, Maja Noman, Paul Rutgeerts, Karolien Van den Broeck, Severine Vermeire, Raf Bisschops
Publikováno v:
Journal of Crohn's and Colitis. 11:1085-1089
Introduction Vedolizumab has proven efficacy in inflammatory bowel disease [IBD], but long-term mucosal healing in Crohn's disease [CD], as well as the incidence of colorectal neoplasia in IBD, among patients treated with vedolizumab have not been st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de220547cb94ecfdd5a68b3bd0f7f308
https://doi.org/10.1093/ecco-jcc/jjx048
https://doi.org/10.1093/ecco-jcc/jjx048
Autor:
Erwin Dreesen, Severine Vermeire, Evelien Mertens, Marc Ferrante, An Outtier, Ann Gils, Ganel Schops, Bram Verstockt, Sophie Tops, Maja Noman, Gert Van Assche
Publikováno v:
Journal of Crohn'scolitis. 14(3)
Background and Objectives Vedolizumab has demonstrated efficacy and safety in patients with Crohn's disease [CD] and ulcerative colitis [UC]. Endoscopic outcome data are limited, especially in anti-tumour necrosis factor [TNF] naïve patients. The pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b20273a7ac0d811cc8df1e07142b764
https://pubmed.ncbi.nlm.nih.gov/31504343
https://pubmed.ncbi.nlm.nih.gov/31504343
Autor:
Bram Verstockt, Severine Vermeire, Nathalie Van den Berghe, Maja Noman, Isolde Aerden, Marc Ferrante, Griet Compernolle, Gert Van Assche, An Outtier, Ann Gils, Erwin Dreesen
Background and Aims Ustekinumab, an anti-IL12/23p40 monoclonal antibody, has been approved for Crohn’s disease [CD]. Real-life data in CD patients receiving ustekinumab intravenously [IV] during induction, followed by subcutaneous [SC] maintenance,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2359874bc6f622265472e1110fce44ed
https://lirias.kuleuven.be/handle/123456789/633945
https://lirias.kuleuven.be/handle/123456789/633945
Autor:
H Peters, P Bossuyt, Joris Dutré, Evelien Humblet, Claire Liefferinckx, E Macken, Bram Verstockt, Edouard Louis, J F Rahier, M. De Vos, D Staessen, P Van Hootegem, Denis Franchimont, Severine Vermeire, F Baert, Ann Gils, C Van Kemseke, W Van Moerkercke, Maja Noman
Publikováno v:
Journal of Crohn's and Colitis. 13:S044-S045
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d29315fecd7a6164d98f64e31e7a93d4
https://doi.org/10.1093/ecco-jcc/jjy222.067
https://doi.org/10.1093/ecco-jcc/jjy222.067
Autor:
André D'Hoore, Gert Van Assche, Maja Noman, Albert Wolthuis, Paul Rutgeerts, Niels Vande Casteele, Marc Ferrante, Filip Baert, Anthony de Buck van Overstraeten, Ilse Hoffman, Maria Theresa Arias, Thomas Billiet, Ann Gils, Severine Vermeire
Publikováno v:
Clinical Gastroenterology and Hepatology. 13:531-538
Infliximab is effective for patients with refractory ulcerative colitis (UC), but few factors have been identified that predict long-term outcome of therapy. We aimed to identify a panel of markers associated with outcome of infliximab therapy to hel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b3afe53d19122047f431eeb4d4f51df
https://doi.org/10.1016/j.cgh.2014.07.055
https://doi.org/10.1016/j.cgh.2014.07.055
Autor:
Lieven Pouillon, Gert Van Assche, João Sabino, Severine Vermeire, Paul Rutgeerts, Marc Ferrante, Niels Vande Casteele, Ann Gils, Maja Noman
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 16(8)
Background & Aims The Trough Concentration Adapted Infliximab Treatment (TAXIT) trial demonstrated that maintaining infliximab trough concentrations at 3 to 7 μg/mL is most effective at inducing remission in patients with inflammatory bowel diseases
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed920c5b062733883deb3b4b6451a223
https://pubmed.ncbi.nlm.nih.gov/29203225
https://pubmed.ncbi.nlm.nih.gov/29203225
Autor:
Vera Ballet, Maja Noman, Gert Van Assche, Ellen Weyts, Kris Vanhaecht, Marc Ferrante, Sofie Coenen, Severine Vermeire
Publikováno v:
European journal of gastroenterologyhepatology. 29(6)
Inflammatory bowel diseases (IBDs) are chronic gastrointestinal conditions requiring long-term outpatient follow-up, ideally by a dedicated, multidisciplinary team. In this team, the IBD nurse is the key point of access for education, advice, and sup
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a4978f2c81fba4d314d1f0f2fc88875
https://pubmed.ncbi.nlm.nih.gov/28118176
https://pubmed.ncbi.nlm.nih.gov/28118176
Autor:
Ellen Weyts, Cedric Jorissen, Vera Ballet, Paul De Munter, Gert Van Assche, Maja Noman, Sofie Coenen, Severine Vermeire, Marc Ferrante
Publikováno v:
Inflammatory bowel diseases. 23(2)
BACKGROUND Despite the existence of international guidelines, vaccination in patients with inflammatory bowel disease (IBD) has not been integrated optimally. We developed a thorough education program, and compared its influence on vaccination rates
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eef8b370366fe64151003240224992a6
https://pubmed.ncbi.nlm.nih.gov/28079621
https://pubmed.ncbi.nlm.nih.gov/28079621
Autor:
Marc Ferrante, Severine Vermeire, N. Vande Casteele, Maja Noman, Paul Rutgeerts, Ann Gils, Filip Baert, Sophie Tops, G. Van Assche
Publikováno v:
Alimentary Pharmacology & Therapeutics. 40:1324-1332
SummaryBackground Data for adalimumab in ulcerative colitis after prior use of infliximab are scarce. Aims To study adalimumab response rates and predictors of response in ulcerative colitis, including drug concentrations. Methods In this single cent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5937e3921e63ece99ea2ac6d608474b2
https://doi.org/10.1111/apt.12968
https://doi.org/10.1111/apt.12968